Compare Star Bulk Carriers Corp (SBLK) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Star Bulk Carriers Corp vs Sanofi SA — how do they compare? Star Bulk Carriers Corp trades at $29.7 (market cap $3.54B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 26.9× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays the higher dividend (6.17%). Which is the better fit depends on your goals — on Pluang, investors hold Star Bulk Carriers Corp for 24 Days and Sanofi SA for 94 Days on average.
| SBLK | SNY | |
|---|---|---|
Market Cap | $3.54B | $95.18B |
Volume | 1,437,622 | 2,995,646 |
Sector | Industrials | Health |
52-Week High | $32.49 | $52.34 |
52-Week Low | $16.79 | $39.51 |
Typical Hold Time | 24 Days | 94 Days |
Enterprise Value | $4.22B | $114.48B |
Dividend Yield | 6.17% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Star Bulk Carriers (SBLK) trades at $30.47, up 2.63% today, with a bullish technical signal from moving averages and consistent earnings beats in recent quarters. The company reported strong Q2 2026 EPS of $1.21, exceeding expectations, and maintains a 100% free cash flow distribution policy, highlighted by a $0.90 dividend for H2 2026. Valuation metrics show a P/E of 11.95 and EV/EBITDA of 8.34, indicating reasonable pricing relative to earnings.
The outlook remains positive due to robust earnings growth, shareholder returns, and insider buying, but risks include shipping market volatility and reliance on global trade cycles. Analyst consensus is bullish with 14 buy ratings, supporting potential upside if operational momentum continues.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
